Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection

World Journal of Gastroenterology

Volumn 20, Issue 32, 2014, Pages 11182-11198

  Becker, Andrew E ^a   Hernandez, Yasmin G ^a   Frucht, Harold ^b   Lucas, Aimee L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

BRCA; Genetic predisposition to disease; Hereditary breast and ovarian cancer syndrome; Lynch syndrome; p16; PALB2; Pancreas cancer screening; Pancreatic neoplasms; Pancreatitis; Peutz Jeghers

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 19-9 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPITHELIAL CELL ADHESION MOLECULE; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; HYDROCARBON; INTERLEUKIN 11; INTERLEUKIN 6; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TUMOR MARKER;

ALCOHOL CONSUMPTION; ATAXIA TELANGIECTASIA; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC PANCREATITIS; CYSTIC FIBROSIS; DIET; EARLY DIAGNOSIS; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; FAMILIAL PANCREATIC CANCER; FAMILY HISTORY; FANCONI ANEMIA; GASTRECTOMY BILLROTH II; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HELICOBACTER INFECTION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); MUCINOUS CYSTIC NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CARCINOMA; PANCREATITIS; PATIENT HISTORY OF CHOLECYSTECTOMY; PEUTZ JEGHERS SYNDROME; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TOBACCO USE; CARCINOMA, PANCREATIC DUCTAL; COMORBIDITY; GENETIC PREDISPOSITION; GENETICS; LIFESTYLE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR;

CARCINOMA, PANCREATIC DUCTAL; COMORBIDITY; EARLY DETECTION OF CANCER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84909587816     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i32.11182     Document Type: Review

References (191)

1. American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society, 2013
2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Available from: URL: http://seer.cancer.gov/csr/1975-2010
3. Bartsch DK, Gress TM, Langer P. Familial pancreatic cancer - current knowledge. Nat Rev Gastroenterol Hepatol 2012; 9: 445-453 [PMID: 22664588 DOI: 10.1038/nrgastro.2012.111]
4. Klein AP, de Andrade M, Hruban RH, Bondy M, Schwartz AG, Gallinger S, Lynch HT, Syngal S, Rabe KG, Goggins MG, Petersen GM. Linkage analysis of chromosome 4 in families with familial pancreatic cancer. Cancer Biol Ther 2007; 6: 320-323 [PMID: 17312386]
5. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453 [PMID: 11113065]
6. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94: 1365-1372 [PMID: 12237282]
7. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-1365 [PMID: 12237281]
8. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007; 110: 738-744 [PMID: 17580363 DOI: 10.1002/cncr.22852]
9. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347 [PMID: 23135763 DOI: 10.1136/gutjnl-2012-303108]
10. Permuth-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 2009; 8: 109-117 [PMID: 18763055 DOI: 10.1007/s10689-008-9214-8]
11. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg 2010; 44: 293-311 [PMID: 20919528]
12. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C, Cameron JL, Yeo CJ, Kern S, Hruban RH. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64: 2634-2638 [PMID: 15059921]
13. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003; 3: 23-34 [PMID: 12509764 DOI: 10.1038/nrc970]
14. Kottemann MC, Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 2013; 493: 356-363 [PMID: 23325218 DOI: 10.1038/nature11863]
15. Schroeder TM, Tilgen D, Krüger J, Vogel F. Formal genetics of Fanconi's anemia. Hum Genet 1976; 32: 257-288 [PMID: 939547]
16. Folias A, Matkovic M, Bruun D, Reid S, Hejna J, Grompe M, D'Andrea A, Moses R. BRCA1 interacts directly with the Fanconi anemia protein FANCA. Hum Mol Genet 2002; 11: 2591-2597 [PMID: 12354784]
17. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408 [PMID: 9145676 DOI: 10.1056/NEJM199705153362001]
18. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694-1706 [PMID: 17148771 DOI: 10.1093/jnci/djj465]
19. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 1811-1814 [PMID: 18042939 DOI: 10.1093/jnci/djm203]
20. Skudra S, Sta¯ka A, Puk¸i¯tis A, Sin¸icka O, Pokrotnieks J, Nikitina M, Tracums J, Tihomirova L. Association of genetic variants with pancreatic cancer. Cancer Genet Cytogenet 2007; 179: 76-78 [PMID: 17981219 DOI: 10.1016/j.cancergencyto.20 07.08.002]
21. Moran A, O'Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 2012; 11: 235-242 [PMID: 22187320 DOI: 10.1007/s10689-011-9506-2]
22. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, Kern SE. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56: 5360-5364 [PMID: 8968085]
23. Consortium TBCL. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-1316 [PMID: 10433620]
24. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grützmann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95: 214-221 [PMID: 12569143]
25. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62: 3789-3793 [PMID: 12097290]
26. Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C, Deng L, Devoe C, Chabot JA, Szabolcs M, Ludwig T, Chung WK, Frucht H. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res 2013; 19: 3396-3403 [PMID: 23658460 DOI: 10.1158/1078-0432.CCR-12-3020]
27. Kim DH, Crawford B, Ziegler J, Beattie MS. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer 2009; 8: 153-158 [PMID: 18855126 DOI: 10.1007/s10689-008-9220-x]
28. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217 [PMID: 19264984 DOI: 10.1126/science.1171202]
29. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165-167 [PMID: 17200668 DOI: 10.1038/ng1959]
30. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, Greenhalf W, Bartsch DK. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010; 78: 490-494 [PMID: 20412113 DOI: 10.1111/j.1399-0004.2010.01425.x]
31. Harinck F, Kluijt I, van Mil SE, Waisfisz Q, van Os TA, Aalfs CM, Wagner A, Olderode-Berends M, Sijmons RH, Kuipers EJ, Poley JW, Fockens P, Bruno MJ. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet 2012; 20: 577-579 [PMID: 22166947 DOI: 10.1038/ejhg.2011.226]
32. Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivastava A, Holter S, Rothenmund H, Ghadirian P, Foulkes WD, Gallinger S. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 2009; 137: 1183-1186 [PMID: 19635604 DOI: 10.1053/j.gastro.2009.06.055]
33. Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthäi E, Langer P, Bartsch DK. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 2011; 10: 323-330 [PMID: 21207249 DOI: 10.1007/s10689-010-9414-x]
34. Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011; 71: 2222-2229 [PMID: 21285249 DOI: 10.1158/0008-5472.CAN-10-3958]
35. Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, Petersen G. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005; 65: 383-386 [PMID: 15695377]
36. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003; 63: 2585-2588 [PMID: 12750283]
37. Leung K, Saif MW. BRCA-associated pancreatic cancer: the evolving management. JOP 2013; 14: 149-151 [PMID: 23474559 DOI: 10.6092/1590-8577/1462]
38. van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005; 11: 7508-7515 [PMID: 16243825 DOI: 10.1158/1078-0432.CCR-05-1048]
39. van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004; 165: 651-657 [PMID: 15277238 DOI: 10.1016/S0002-9440(10)63329-9]
40. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134 [PMID: 19553641 DOI: 10.1056/NEJMoa0900212]
41. Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 2011; 31: 1417-1420 [PMID: 21508395]
42. Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol 2014; 12: 715-727; quiz e41-43 [PMID: 23891921 DOI: 10.1016/j.cgh.2013.06.031]
43. de la Chapelle A. The incidence of Lynch syndrome. Fam Cancer 2005; 4: 233-237 [PMID: 16136383 DOI: 10.1007/s10689-004-5811-3]
44. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal S. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009; 302: 1790-1795 [PMID: 19861671 DOI: 10.1001/jama.2009.1529]
45. Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010; 139: 1076-180, 1076-180, [PMID: 20727885 DOI: 10.1053/j.gastro.2010.08.012]
46. Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J 2011; 17: 405-415 [PMID: 22157284 DOI: 10.1097/PPO.0b013e318237e408]
47. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101: 385-398 [PMID: 16454848 DOI: 10.1111/j.1572-0241.2006.00375.x]
48. Björk J, Akerbrant H, Iselius L, Alm T, Hultcrantz R. Epidemiology of familial adenomatous polyposis in Sweden: changes over time and differences in phenotype between males and females. Scand J Gastroenterol 1999; 34: 1230-1235 [PMID: 10636071]
49. Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 1994; 3: 121-125 [PMID: 8199592 DOI: 10.1002/humu.1380030206]
50. Giardiello FM, Offerhaus GJ, Lee DH, Krush AJ, Tersmette AC, Booker SV, Kelley NC, Hamilton SR. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34: 1394-1396 [PMID: 8244108]
51. Maire F, Hammel P, Terris B, Olschwang S, O'Toole D, Sauvanet A, Palazzo L, Ponsot P, Laplane B, Lévy P, Ruszniewski P. Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut 2002; 51: 446-449 [PMID: 12171972]
52. Knudsen AL, Bisgaard ML, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003; 2: 43-55 [PMID: 14574166]
53. Knudsen AL, Bülow S, Tomlinson I, Möslein G, Heinimann K, Christensen IJ. Attenuated familial adenomatous polyposis: results from an international collaborative study. Colorectal Dis 2010; 12: e243-e249 [PMID: 20105204 DOI: 10.1111/j.1463-1318.2010.02218.x]
54. Tomlinson IP, Houlston RS. Peutz-Jeghers syndrome. J Med Genet 1997; 34: 1007-1011 [PMID: 9429144]
55. Korsse SE, Peppelenbosch MP, van Veelen W. Targeting LKB1 signaling in cancer. Biochim Biophys Acta 2013; 1835: 194-210 [PMID: 23287572 DOI: 10.1016/j.bbcan.2012.12.006]
56. Morton JP, Jamieson NB, Karim SA, Athineos D, Ridgway RA, Nixon C, McKay CJ, Carter R, Brunton VG, Frame MC, Ashworth A, Oien KA, Evans TR, Sansom OJ. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 2010; 139: 586-97, 597.e1-6 [PMID: 20452353 DOI: 10.1053/j.gastro.2010.04.055]
57. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007; 44: 99-106 [PMID: 16905682 DOI: 10.1136/jmg.2006.043802]
58. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66: 9818-9828 [PMID: 17047042 DOI: 10.1158/0008-5472.CAN-06-0494]
59. Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, Liu L, Knezetic J, Lassam NJ, Goggins M, Kern S. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002; 94: 84-96 [PMID: 11815963 DOI: 10.1002/cncr.10159]
60. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000; 92: 1006-1010 [PMID: 10861313]
61. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Ma˚sbäck A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92: 1260-1266 [PMID: 10922411]
62. Moskaluk CA, Hruban H, Lietman A, Smyrk T, Fusaro L, Fusaro R, Lynch J, Yeo CJ, Jackson CE, Lynch HT, Kern SE. Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no.148. Online. Hum Mutat 1998; 12: 70 [PMID: 10627132]
63. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333: 970-974 [PMID: 7666916 DOI: 10.1056/NEJM199510123331504]
64. de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, Out-Luiting CJ, Vasen HF, ter Huurne JA, Frants RR, Willemze R, Breuning MH, Gruis NA. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008; 14: 7151-7157 [PMID: 18981015 DOI: 10.1158/1078-0432.CCR-08-0403]
65. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009; 133: 365-374 [PMID: 19260742 DOI: 10.1043/1543-2165-133.3.365]
66. LaRusch J, Whitcomb DC. Genetics of pancreatitis. Curr Opin Gastroenterol 2011; 27: 467-474 [PMID: 21844754 DOI: 10.1097/MOG.0b013e328349e2f8]
67. Schneider A, Suman A, Rossi L, Barmada MM, Beglinger C, Parvin S, Sattar S, Ali L, Khan AK, Gyr N, Whitcomb DC. SPINK1/PSTI mutations are associated with tropical pancreatitis and type II diabetes mellitus in Bangladesh. Gastroenterology 2002; 123: 1026-1030 [PMID: 12360464]
68. Sossenheimer MJ, Aston CE, Preston RA, Gates LK, Ulrich CD, Martin SP, Zhang Y, Gorry MC, Ehrlich GD, Whitcomb DC. Clinical characteristics of hereditary pancreatitis in a large family, based on high-risk haplotype. The Midwest Multicenter Pancreatic Study Group (MMPSG) Am J Gastroenterol 1997; 92: 1113-1116 [PMID: 9219780]
69. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010; 24: 349-358 [PMID: 20510834 DOI: 10.1016/j.bpg.2010.02.007]
70. Maisonneuve P, Marshall BC, Lowenfels AB. Risk of pancreatic cancer in patients with cystic fibrosis. Gut 2007; 56: 1327-1328 [PMID: 17698876 DOI: 10.1136/gut.2007.125278]
71. Cohn JA, Mitchell RM, Jowell PS. The impact of cystic fibrosis and PSTI/SPINK1 gene mutations on susceptibility to chronic pancreatitis. Clin Lab Med 2005; 25: 79-100 [PMID: 15749233 DOI: 10.1016/j.cll.2004.12.007]
72. Weiss FU, Simon P, Bogdanova N, Mayerle J, Dworniczak B, Horst J, Lerch MM. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut 2005; 54: 1456-1460 [PMID: 15987793 DOI: 10.1136/gut.2005.064808]
73. Gukovsky I, Li N, Todoric J, Gukovskaya A, Karin M. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology 2013; 144: 1199-209.e4 [PMID: 23622129 DOI: 10.1053/j.gastro.2013.02.007]
74. Masamune A, Watanabe T, Kikuta K, Shimosegawa T. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol 2009; 7: S48-S54 [PMID: 19896099 DOI: 10.1016/j.cgh.2009.07.038]
75. Greenberger S, Berkun Y, Ben-Zeev B, Levi YB, Barziliai A, Nissenkorn A. Dermatologic manifestations of ataxia-telangiectasia syndrome. J Am Acad Dermatol 2013; 68: 932-936 [PMID: 23360865 DOI: 10.1016/j.jaad.2012.12.950]
76. Swift M, Chase CL, Morrell D. Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 1990; 46: 21-27 [PMID: 2184933]
77. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, Papadopoulos N, Hruban RH, Kinzler KW, Klein AP. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012; 2: 41-46 [PMID: 22585167 DOI: 10.1158/2159-8290.CD-11-0194]
78. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831-1836 [PMID: 1961222 DOI: 10.1056/NEJM199112263252602]
79. Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 1986; 39: 573-583 [PMID: 3788973]
80. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987; 316: 1289-1294 [PMID: 3574400 DOI: 10.1056/NEJM198705213162101]
81. Morrell D, Chase CL, Swift M. Cancers in 44 families with ataxia-telangiectasia. Cancer Genet Cytogenet 1990; 50: 119-123 [PMID: 2253179]
82. Egawa N, Lin Y, Tabata T, Kuruma S, Hara S, Kubota K, Kamisawa T. ABO blood type, long-standing diabetes, and the risk of pancreatic cancer. World J Gastroenterol 2013; 19: 2537-2542 [PMID: 23674856 DOI: 10.3748/wjg.v19.i16.2537]
83. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Clavel-Chapelon F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Fox JW, Gallinger S, Gaziano JM, Giovannucci EL, Goggins M, González CA, Hallmans G, Hankinson SE, Hassan M, Holly EA, Hunter DJ, Hutchinson A, Jackson R, Jacobs KB, Jenab M, Kaaks R, Klein AP, Kooperberg C, Kurtz RC, Li D, Lynch SM, Mandelson M, McWilliams RR, Mendelsohn JB, Michaud DS, Olson SH, Overvad K, Patel AV, Peeters PH, Rajkovic A, Riboli E, Risch HA, Shu XO, Thomas G, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hartge P, Hoover RN. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009; 41: 986-990 [PMID: 19648918 DOI: 10.1038/ng.429]
84. Risch HA, Yu H, Lu L, Kidd MS. ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst 2010; 102: 502-505 [PMID: 20181960 DOI: 10.1093/jnci/djq007]
85. Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB. ABO blood group and cancer. Eur J Cancer 2010; 46: 3345-3350 [PMID: 20833034 DOI: 10.1016/j.ejca.2010.08.009]
86. Wolpin BM, Kraft P, Gross M, Helzlsouer K, Buenode-Mesquita HB, Steplowski E, Stolzenberg-Solomon RZ, Arslan AA, Jacobs EJ, Lacroix A, Petersen G, Zheng W, Albanes D, Allen NE, Amundadottir L, Anderson G, Boutron-Ruault MC, Buring JE, Canzian F, Chanock SJ, Clipp S, Gaziano JM, Giovannucci EL, Hallmans G, Hankinson SE, Hoover RN, Hunter DJ, Hutchinson A, Jacobs K, Kooperberg C, Lynch SM, Mendelsohn JB, Michaud DS, Overvad K, Patel AV, Rajkovic A, Sanchéz MJ, Shu XO, Slimani N, Thomas G, Tobias GS, Trichopoulos D, Vineis P, Virtamo J, Wactawski-Wende J, Yu K, Zeleniuch-Jacquotte A, Hartge P, Fuchs CS. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 2010; 70: 1015-1023 [PMID: 20103627 DOI: 10.1158/0008-5472.CAN-09-2993]
87. Greer JB, LaRusch J, Brand RE, O'Connell MR, Yadav D, Whitcomb DC. ABO blood group and chronic pancreatitis risk in the NAPS2 cohort. Pancreas 2011; 40: 1188-1194 [PMID: 21792085 DOI: 10.1097/MPA.0b013e3182232975]
88. McFaul CD, Greenhalf W, Earl J, Howes N, Neoptolemos JP, Kress R, Sina-Frey M, Rieder H, Hahn S, Bartsch DK. Anticipation in familial pancreatic cancer. Gut 2006; 55: 252-258 [PMID: 15972300 DOI: 10.1136/gut.2005.065045]
89. Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002; 23: 133-149 [PMID: 12214307 DOI: 10.1002/gepi.1102]
90. Brentnall TA. Arousal of cancer-associated stromal fibroblasts: palladin-activated fibroblasts promote tumor invasion. Cell Adh Migr 2012; 6: 488-494 [PMID: 23076142 DOI: 10.4161/cam.21453]
91. Evans JP, Burke W, Chen R, Bennett RL, Schmidt RA, Dellinger EP, Kimmey M, Crispin D, Brentnall TA, Byrd DR. Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. J Med Genet 1995; 32: 330-335 [PMID: 7616537]
92. Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, Otey CA, Crispin DA, George RD, Whitcomb DC, Brentnall TA. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006; 3: e516 [PMID: 17194196 DOI: 10.1371/journal.pmed.0030516]
93. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and metaanalysis. Langenbecks Arch Surg 2008; 393: 535-545 [PMID: 18193270 DOI: 10.1007/s00423-007-0266-2]
94. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 2004; 34: 238-244 [PMID: 15231857]
95. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001; 286: 169-170 [PMID: 11448279]
96. Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Bertuccio P, Gao YT, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Boffetta P, La Vecchia C. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2012; 23: 1880-1888 [PMID: 22104574 DOI: 10.1093/annonc/mdr541]
97. Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, Canzian F, Steplowski E, Arslan AA, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Amundadottir L, Bingham SA, Boffetta P, Boutron-Ruault MC, Chanock SJ, Clipp S, Hoover RN, Jacobs K, Johnson KC, Kooperberg C, Luo J, Messina C, Palli D, Patel AV, Riboli E, Shu XO, Rodriguez Suarez L, Thomas G, Tjønneland A, Tobias GS, Tong E, Trichopoulos D, Virtamo J, Ye W, Yu K, Zeleniuch-Jacquette A, Bueno-de-Mesquita HB, Stolzenberg-Solomon RZ. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009; 170: 403-413 [PMID: 19561064 DOI: 10.1093/aje/kwp134]
98. Bonelli L, Aste H, Bovo P, Cavallini G, Felder M, Gusmaroli R, Morandini E, Ravelli P, Briglia R, Lombardo L, De Micheli A, Pugliese V. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 2003; 27: 143-149 [PMID: 12883263]
99. Boyle P, Maisonneuve P, Bueno de Mesquita B, Ghadirian P, Howe GR, Zatonski W, Baghurst P, Moerman CJ, Simard A, Miller AB, Przewoniak K, McMichael AJ, Hsieh CC, Walker AM. Cigarette smoking and pancreas cancer: a case control study of the search programme of the IARC. Int J Cancer 1996; 67: 63-71 [PMID: 8690527 DOI: 10.1002/(SICI)1097-021 5(19960703)67]
100. Ji BT, Chow WH, Dai Q, McLaughlin JK, Benichou J, Hatch MC, Gao YT, Fraumeni JF. Cigarette smoking and alcohol consumption and the risk of pancreatic cancer: a case-control study in Shanghai, China. Cancer Causes Control 1995; 6: 369-376 [PMID: 7548725]
101. Villeneuve PJ, Johnson KC, Mao Y, Hanley AJ. Environmental tobacco smoke and the risk of pancreatic cancer: findings from a Canadian population-based case-control study. Can J Public Health 2004; 95: 32-37 [PMID: 14768739]
102. Jarosz M, Sekuła W, Rychlik E. Influence of diet and tobacco smoking on pancreatic cancer incidence in poland in 1960-2008. Gastroenterol Res Pract 2012; 2012: 682156 [PMID: 23319943 DOI: 10.1155/2012/682156]
103. Duell EJ. Epidemiology and potential mechanisms of tobacco smoking and heavy alcohol consumption in pancreatic cancer. Mol Carcinog 2012; 51: 40-52 [PMID: 22162230 DOI: 10.1002/mc.20786]
104. Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003; 124: 1292-1299 [PMID: 12730869]
105. Genkinger JM, Spiegelman D, Anderson KE, Bergkvist L, Bernstein L, van den Brandt PA, English DR, Freudenheim JL, Fuchs CS, Giles GG, Giovannucci E, Hankinson SE, Horn-Ross PL, Leitzmann M, Männistö S, Marshall JR, McCullough ML, Miller AB, Reding DJ, Robien K, Rohan TE, Schatzkin A, Stevens VL, Stolzenberg-Solomon RZ, Verhage BA, Wolk A, Ziegler RG, Smith-Warner SA. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev 2009; 18: 765-776 [PMID: 19258474 DOI: 10.1158/1055-9965. EPI-08-0880]
106. Tramacere I, Scotti L, Jenab M, Bagnardi V, Bellocco R, Rota M, Corrao G, Bravi F, Boffetta P, La Vecchia C. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer 2010; 126: 1474-1486 [PMID: 19816941 DOI: 10.1002/ijc.24936]
107. Yeo TP, Lowenfels AB. Demographics and epidemiology of pancreatic cancer. Cancer J 2012; 18: 477-484 [PMID: 23187833 DOI: 10.1097/PPO.0b013e3182756803]
108. Pandol SJ, Raraty M. Pathobiology of alcoholic pancreatitis. Pancreatology 2007; 7: 105-114 [PMID: 17592222 DOI: 10.1159/000104235]
109. Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer 2012; 106: 603-607 [PMID: 22240790 DOI: 10.1038/bjc.2011.585]
110. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer 2007; 120: 1993-1998 [PMID: 17266034 DOI: 10.1002/ijc.22535]
111. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423]
112. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, Lukanova A, Johansen D, Concin H, Tretli S, Hallmans G, Jonsson H, Stattin P. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 2009; 6: e1000201 [PMID: 20027213 DOI: 10.1371/journal.pmed.1000201]
113. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283: 2552-2558 [PMID: 10815119]
114. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981-987 [PMID: 18395079 DOI: 10.1053/j.gastro.2008.01.039]
115. Stattin P, Björ O, Ferrari P, Lukanova A, Lenner P, Lindahl B, Hallmans G, Kaaks R. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007; 30: 561-567 [PMID: 17327321 DOI: 10.2337/dc06-0922]
116. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202 [PMID: 15644546 DOI: 10.1001/jama.293.2.194]
117. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005; 294: 2872-2878 [PMID: 16352795 DOI: 10.1001/jama.294.22.2872]
118. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083 [PMID: 15886696 DOI: 10.1038/sj.bjc.6602619]
119. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and metaanalysis. Br J Cancer 2007; 96: 507-509 [PMID: 17224924 DOI: 10.1038/sj.bjc.6603571]
120. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134: 95-101 [PMID: 18061176 DOI: 10.1053/j.gastro.2007.10.040]
121. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer 2012; 19: F9-F26 [PMID: 22843556 DOI: 10.1530/ERC-12-0105]
122. Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998; 9: 403-410 [PMID: 9794172]
123. Chow WH, Gridley G, Nyrén O, Linet MS, Ekbom A, Fraumeni JF, Adami HO. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995; 87: 930-931 [PMID: 7666483]
124. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129: 504-511 [PMID: 16083707 DOI: 10.1016/j.gastro.2005.05.007]
125. Fogar P, Pasquali C, Basso D, Sperti C, Panozzo MP, Tessari G, D'Angeli F, Del Favero G, Plebani M. Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res 1994; 14: 2827-2830 [PMID: 7532931]
126. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80: 1047-1050 [PMID: 8402064]
127. Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology 2011; 11: 279-294 [PMID: 21757968 DOI: 10.1159/000329188]
128. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011; 40: 339-351 [PMID: 21412116 DOI: 10.1097/MPA.0b013e318209e05d]
129. Hardt PD, Brendel MD, Kloer HU, Bretzel RG. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? Diabetes Care 2008; 31 Suppl 2: S165-S169 [PMID: 18227480 DOI: 10.2337/dc08-s244]
130. Andersen DK. Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis. Pancreas 2007; 35: 1-15 [PMID: 17575539 DOI: 10.1097/mpa.0b013e31805d01b0]
131. Seymour NE, Brunicardi FC, Chaiken RL, Lebovitz HE, Chance RE, Gingerich RL, Elahi D, Andersen DK. Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. Surgery 1988; 104: 119-129 [PMID: 3041640]
132. Brunicardi FC, Chaiken RL, Ryan AS, Seymour NE, Hoffmann JA, Lebovitz HE, Chance RE, Gingerich RL, Andersen DK, Elahi D. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 1996; 81: 3566-3572 [PMID: 8855802]
133. Ding XZ, Fehsenfeld DM, Murphy LO, Permert J, Adrian TE. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 2000; 21: 310-320 [PMID: 11039477]
134. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305 [PMID: 15849206 DOI: 10.1136/bmj.38415.708634.F7]
135. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-1625 [PMID: 19564453 DOI: 10.2337/dc08-2175]
136. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11: 20 [PMID: 21241523 DOI: 10.1186/1471-2407-11-20]
137. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-488 [PMID: 19375425 DOI: 10.1053/j.gastro.2009.04.013]
138. Lin G, Zeng Z, Wang X, Wu Z, Wang J, Wang C, Sun Q, Chen Y, Quan H. Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies. Cancer Causes Control 2012; 23: 59-67 [PMID: 22008981 DOI: 10.1007/s10552-011-9856-y]
139. McDonnell CO, Bailey I, Stumpf T, Walsh TN, Johnson CD. The effect of cholecystectomy on plasma cholecystokinin. Am J Gastroenterol 2002; 97: 2189-2192 [PMID: 12358231 DOI: 10.1111/j.1572-0241.2002.05971.x]
140. Matters GL, McGovern C, Harms JF, Markovic K, Anson K, Jayakumar C, Martenis M, Awad C, Smith JP. Role of endogenous cholecystokinin on growth of human pancreatic cancer. Int J Oncol 2011; 38: 593-601 [PMID: 21186400 DOI: 10.3892/ijo.2010.886]
141. Chu M, Rehfeld JF, Borch K. Chronic endogenous hypercholecystokininemia promotes pancreatic carcinogenesis in the hamster. Carcinogenesis 1997; 18: 315-320 [PMID: 9054623]
142. Ura H, Makino T, Ito S, Tsutsumi M, Kinugasa T, Kamano T, Ichimiya H, Konishi Y. Combined effects of cholecystectomy and lithocholic acid on pancreatic carcinogenesis of N-nitrosobis(2-hydroxypropyl)amine in Syrian golden hamsters. Cancer Res 1986; 46: 4782-4786 [PMID: 3731125]
143. Luo J, Nordenvall C, Nyrén O, Adami HO, Permert J, Ye W. The risk of pancreatic cancer in patients with gastric or duodenal ulcer disease. Int J Cancer 2007; 120: 368-372 [PMID: 17044024 DOI: 10.1002/ijc.22123]
144. Gong Y, Zhou Q, Zhou Y, Lin Q, Zeng B, Chen R, Li Z. Gastrectomy and risk of pancreatic cancer: systematic review and meta-analysis of observational studies. Cancer Causes Control 2012; 23: 1279-1288 [PMID: 22674223 DOI: 10.1007/s10552-012-0005-z]
145. Trikudanathan G, Philip A, Dasanu CA, Baker WL. Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP 2011; 12: 26-31 [PMID: 21206097]
146. Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M, Abbruzzese JL. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 2008; 26: 4557-4562 [PMID: 18824707 DOI: 10.1200/JCO.2008.17.3526]
147. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 2009; 49: 116-123 [PMID: 19085911 DOI: 10.1002/hep.22606]
148. Andreotti G, Silverman DT. Occupational risk factors and pancreatic cancer: a review of recent findings. Mol Carcinog 2012; 51: 98-108 [PMID: 22162234 DOI: 10.1002/mc.20779]
149. Berman JJ, Albores-Saavedra J, Bostwick D, Delellis R, Eble J, Hamilton SR, Hruban RH, Mutter GL, Page D, Rohan T, Travis W, Henson DE. Precancer: a conceptual working definition - results of a Consensus Conference. Cancer Detect Prev 2006; 30: 387-394 [PMID: 17079091 DOI: 10.1016/j.cdp.2006.09.002]
150. Hruban RH, Maitra A, Kern SE, Goggins M. Precursors to pancreatic cancer. Gastroenterol Clin North Am 2007; 36: 831-49, vi [PMID: 17996793 DOI: 10.1016/j.gtc.2007.08.012]
151. Scarlett CJ, Salisbury EL, Biankin AV, Kench J. Precursor lesions in pancreatic cancer: morphological and molecular pathology. Pathology 2011; 43: 183-200 [PMID: 21436628 DOI: 10.1097/PAT.0b013e3283445e3a]
152. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003; 16: 996-1006 [PMID: 14559982 DOI: 10.1097/01.MP.0000087422.24733.62]
153. Lüttges J, Reinecke-Lüthge A, Möllmann B, Menke MA, Clemens A, Klimpfinger M, Sipos B, Klöppel G. Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Arch 1999; 435: 461-468 [PMID: 10592048]
154. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976; 36: 2690-2698 [PMID: 1277176]
155. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-2972 [PMID: 10955772]
156. Hruban RH, Tsai YC, Kern SE. Pancreatic Cancer. Vogelstein B, Kinzler KW. The Genetic Basis of Human Cancer. New York: McGraw-Hill, 1998: 659
157. Brune K, Abe T, Canto M, O'Malley L, Klein AP, Maitra A, Volkan Adsay N, Fishman EK, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006; 30: 1067-1076 [PMID: 16931950]
158. Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, Johnson PT, Fishman EK, Hruban RH. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 2008; 191: 802-807 [PMID: 18716113 DOI: 10.2214/AJR.07.3340]
159. Kimura W, Nagai H, Kuroda A, Muto T, Esaki Y. Analysis of small cystic lesions of the pancreas. Int J Pancreatol 1995; 18: 197-206 [PMID: 8708390 DOI: 10.1007/BF02784942]
160. Lee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 2010; 105: 2079-2084 [PMID: 20354507 DOI: 10.1038/ajg.2010.122]
161. Goh BK, Tan YM, Chung YF, Chow PK, Cheow PC, Wong WK, Ooi LL. A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathological features of 344 patients. World J Surg 2006; 30: 2236-2245 [PMID: 17103100 DOI: 10.1007/s00268-006-0126-1]
162. Zamboni G, Scarpa A, Bogina G, Iacono C, Bassi C, Talamini G, Sessa F, Capella C, Solcia E, Rickaert F, Mariuzzi GM, Klöppel G. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999; 23: 410-422 [PMID: 10199470]
163. Crippa S, Salvia R, Warshaw AL, Domínguez I, Bassi C, Falconi M, Thayer SP, Zamboni G, Lauwers GY, Mino-Kenudson M, Capelli P, Pederzoli P, Castillo CF. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg 2008; 247: 571-579 [PMID: 18362619 DOI: 10.1097/SLA.0b013e31811f4449]
164. Yamao K, Yanagisawa A, Takahashi K, Kimura W, Doi R, Fukushima N, Ohike N, Shimizu M, Hatori T, Nobukawa B, Hifumi M, Kobayashi Y, Tobita K, Tanno S, Sugiyama M, Miyasaka Y, Nakagohri T, Yamaguchi T, Hanada K, Abe H, Tada M, Fujita N, Tanaka M. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovariantype stroma: a multi-institutional study of the Japan pancreas society. Pancreas 2011; 40: 67-71 [PMID: 20924309 DOI: 10.1097/MPA.0b013e3181f749d3]
165. Le Baleur Y, Couvelard A, Vullierme MP, Sauvanet A, Hammel P, Rebours V, Maire F, Hentic O, Aubert A, Ruszniewski P, Lévy P. Mucinous cystic neoplasms of the pancreas: definition of preoperative imaging criteria for high-risk lesions. Pancreatology 2011; 11: 495-499 [PMID: 22042244 DOI: 10.1159/000332041]
166. Crippa S, Fernández-Del Castillo C, Salvia R, Finkelstein D, Bassi C, Domínguez I, Muzikansky A, Thayer SP, Falconi M, Mino-Kenudson M, Capelli P, Lauwers GY, Partelli S, Pederzoli P, Warshaw AL. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 2010; 8: 213-219 [PMID: 19835989 DOI: 10.1016/j.cgh.2009.10.001]
167. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-620 [PMID: 21620466 DOI: 10.1016/S0140-6736(10)62307-0]
168. Farrell JJ, Fernández-del Castillo C. Pancreatic cystic neoplasms: management and unanswered questions. Gastroenterology 2013; 144: 1303-1315 [PMID: 23622140 DOI: 10.1053/j.gastro.2013.01.073]
169. Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg 2007; 246: 644-51; discussion 651-4 [PMID: 17893501 DOI: 10.1097/SLA.0b013e318155a9e5]
170. Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, Thayer SP, Lauwers GY, Capelli P, Mino-Kenudson M, Razo O, McGrath D, Pederzoli P, Fernández-Del Castillo C. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007; 133: 72-9; quiz 309-10 [PMID: 17631133 DOI: 10.1053/j.gastro.2007.05.010]
171. Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183-197 [PMID: 22687371 DOI: 10.1016/j.pan.2012.04.004]
172. Valsangkar NP, Morales-Oyarvide V, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernández-del Castillo C. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery 2012; 152: S4-12 [PMID: 22770958 DOI: 10.1016/j.surg.2012.05.033]
173. Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, Morohoshi T, Egawa S, Unno M, Takao S, Osako M, Yonezawa S, Mino-Kenudson M, Lauwers GY, Yamaguchi H, Ban S, Shimizu M. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 2011; 60: 509-516 [PMID: 21193453 DOI: 10.1136/gut.2010.210567]
174. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, Petersen G, Klein AP, Axilbund J, Griffin C, Syngal S, Saltzman JR, Mortele KJ, Lee J, Tamm E, Vikram R, Bhosale P, Margolis D, Farrell J, Goggins M. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012; 142: 796-804; quiz e14-5 [PMID: 22245846 DOI: 10.1053/j.gastro.2012.01.005]
175. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011; 17: 805-816 [PMID: 21325298 DOI: 10.1158/1078-0432.CCR-10-0248]
176. Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J 2012; 18: 530-538 [PMID: 23187839 DOI: 10.1097/PPO.0b013e31827654ea]
177. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350-355 [PMID: 2183589]
178. Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, Villadolid D, Zervos E, Rosemurgy A. CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg 2009; 13: 349-353 [PMID: 18972170 DOI: 10.1007/s11605-008-0696-3]
179. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009; 6: e1000046 [PMID: 19360088 DOI: 10.1371/journal.pmed.1000046]
180. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, Canto MI. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007; 56: 1460-1469 [PMID: 17872573 DOI: 10.1136/gut.2006.108456]
181. Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince MA, Chung WK, Fine RL, Chabot JA, Frucht H. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010; 16: 5028-5037 [PMID: 20876795 DOI: 10.1158/1078-0432.CCR-09-3209]
182. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999; 131: 247-255 [PMID: 10454945]
183. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 2001; 1: 477-485 [PMID: 12120228 DOI: 10.1159/000055851]
184. Kimmey MB, Bronner MP, Byrd DR, Brentnall TA. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002; 56: S82-S86 [PMID: 12297755]
185. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, Ali SZ, Jagannath S, Petersen GM, Fishman EK, Piantadosi S, Giardiello FM, Hruban RH. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621 [PMID: 15224285]
186. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, Fishman EK, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy SV, Kalloo AN. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4: 766-781; quiz 665 [PMID: 16682259 DOI: 10.1016/j.cgh.2006.02.005]
187. Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009; 104: 2175-2181 [PMID: 19491823 DOI: 10.1038/ajg.2009.276]
188. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, Rothmund M, Bartsch DK. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009; 58: 1410-1418 [PMID: 19470496 DOI: 10.1136/gut.2008.171611]
189. Ludwig E, Olson SH, Bayuga S, Simon J, Schattner MA, Gerdes H, Allen PJ, Jarnagin WR, Kurtz RC. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011; 106: 946-954 [PMID: 21468009 DOI: 10.1038/ajg.2011.65]
190. Vasen HF, Wasser M, van Mil A, Tollenaar RA, Konstantinovski M, Gruis NA, Bergman W, Hes FJ, Hommes DW, Offerhaus GJ, Morreau H, Bonsing BA, de Vos tot Nederveen Cappel WH. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16- Leiden mutation. Gastroenterology 2011; 140: 850-856 [PMID: 21129377 DOI: 10.1053/j.gastro.2010.11.048]
191. Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R, Wilson S, Moore M, Narod S, Jhaveri K, Haider MA, Gallinger S. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 2012; 16: 771-783 [PMID: 22127781 DOI: 10.1007/s11605-011-1781-6]